Early results from the phase 1 inMMyCAR trial suggest that KLN-1010 could simplify CAR T-cell therapy for patients with relapsed or refractory multiple myeloma. Unlike traditional CAR T treatments, which require collecting and engineering a patient’s T cells in a laboratory, KLN-1010 generates anti-BCMA CAR T cells directly inside the body. This eliminates the need for cell collection, external manufacturing, and pre-treatment chemotherapy, reducing treatment time to about 13 days.
The study included 18 heavily pretreated patients, many with high-risk disease features. All evaluable patients responded to treatment, producing a 100% overall response rate. Among patients followed for at least four months, 67% achieved a stringent complete response, while the remaining patients achieved very good partial responses. All evaluable patients also became minimal residual disease (MRD) negative by one month.
The therapy showed a manageable safety profile. Most patients experienced only mild cytokine release syndrome, serious neurotoxicity was rare, and no severe infections were reported during the first three months. These findings support further development of KLN-1010 as a potentially more accessible and convenient CAR T-cell therapy.